These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 38441191)

  • 21. SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan (Response).
    Ogata T; Tanaka H
    Emerg Infect Dis; 2024 Jan; 30(1):207. PubMed ID: 38146992
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevalence of saliva immunoglobulin A antibodies reactive with severe acute respiratory syndrome coronavirus 2 among Japanese people unexposed to the virus.
    Tsukinoki K; Yamamoto T; Saito J; Sakaguchi W; Iguchi K; Inoue Y; Ishii S; Sato C; Yokoyama M; Shiraishi Y; Kato N; Shimada H; Makabe A; Saito A; Tanji M; Nagaoka I; Saruta J; Yamaguchi T; Kimoto S; Yamaguchi H
    Microbiol Immunol; 2022 Aug; 66(8):403-410. PubMed ID: 35607844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.
    Dashraath P; Wong JLJ; Lim MXK; Lim LM; Li S; Biswas A; Choolani M; Mattar C; Su LL
    Am J Obstet Gynecol; 2020 Jun; 222(6):521-531. PubMed ID: 32217113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
    Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
    Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmissibility of SARS-CoV-2 B.1.1.214 and Alpha Variants during 4 COVID-19 Waves, Kyoto, Japan, January 2020-June 2021.
    Matsumura Y; Nagao M; Yamamoto M; Tsuchido Y; Noguchi T; Shinohara K; Yukawa S; Inoue H; Ikeda T
    Emerg Infect Dis; 2022 Aug; 28(8):1569-77. PubMed ID: 35710464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivermectin for preventing and treating COVID-19.
    Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Arashiro T; Miwa M; Nakagawa H; Takamatsu J; Oba K; Fujimi S; Kikuchi H; Iwasawa T; Kanbe F; Oyama K; Kanai M; Ogata Y; Asakura T; Asami T; Mizuno K; Sugita M; Jinta T; Nishida Y; Kato H; Atagi K; Higaki T; Nakano Y; Tsutsumi T; Doi K; Okugawa S; Ueda A; Nakamura A; Yoshida T; Shimada-Sammori K; Shimizu K; Fujita Y; Okochi Y; Tochitani K; Nakanishi A; Rinka H; Taniyama D; Yamaguchi A; Uchikura T; Matsunaga M; Aono H; Hamaguchi M; Motoda K; Nakayama S; Yamamoto K; Oka H; Tanaka K; Inoue T; Kobayashi M; Fujitani S; Tsukahara M; Takeda S; Stucky A; Suzuki T; Smith C; Hibberd M; Ariyoshi K; Fujino Y; Arima Y; Takeda S; Hashimoto S; Suzuki M
    Vaccine; 2024 Jan; 42(3):677-688. PubMed ID: 38114409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study.
    Ishii M; Terai H; Kabata H; Masaki K; Chubachi S; Tateno H; Nakamura M; Nishio K; Koh H; Watanabe R; Ueda S; Terashima T; Suzuki Y; Yagi K; Miyao N; Minematsu N; Inoue T; Nakachi I; Namkoong H; Okamori S; Ikemura S; Kamata H; Yasuda H; Kawada I; Hasegawa N; Fukunaga K;
    J Infect; 2020 Nov; 81(5):e3-e5. PubMed ID: 32920063
    [No Abstract]   [Full Text] [Related]  

  • 29. Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan.
    Okuhama A; Ishikane M; Katagiri D; Kanda K; Nakamoto T; Kinoshita N; Nunose N; Fukaya T; Kondo I; Katano H; Suzuki T; Ohmagari N; Hinoshita F
    Emerg Infect Dis; 2020 Nov; 26(11):2758-2761. PubMed ID: 32730734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan.
    Fujino T; Nomoto H; Kutsuna S; Ujiie M; Suzuki T; Sato R; Fujimoto T; Kuroda M; Wakita T; Ohmagari N
    Emerg Infect Dis; 2021 Apr; 27(4):1243-5. PubMed ID: 33567247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents.
    Cegolon L; Javanbakht M; Mastrangelo G
    Int J Hyg Environ Health; 2020 Sep; 230():113605. PubMed ID: 32898838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020.
    Arima Y; Shimada T; Suzuki M; Suzuki T; Kobayashi Y; Tsuchihashi Y; Nakamura H; Matsumoto K; Takeda A; Kadokura K; Sato T; Yahata Y; Nakajima N; Tobiume M; Takayama I; Kageyama T; Saito S; Nao N; Matsui T; Sunagawa T; Hasegawa H; Ohnishi M; Wakita T
    Emerg Infect Dis; 2020 Jul; 26(7):1596-600. PubMed ID: 32275498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel indicator for the spread of new coronavirus disease 2019 and its association with human mobility in Japan.
    Kawakami Y; Nojiri S; Nakamoto D; Irie Y; Miyazawa S; Kuroki M; Nishizaki Y
    Sci Rep; 2023 Jan; 13(1):115. PubMed ID: 36596837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Removal of Airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Microbial Bioaerosols by Air Filtration on Coronavirus Disease 2019 (COVID-19) Surge Units.
    Conway Morris A; Sharrocks K; Bousfield R; Kermack L; Maes M; Higginson E; Forrest S; Pereira-Dias J; Cormie C; Old T; Brooks S; Hamed I; Koenig A; Turner A; White P; Floto RA; Dougan G; Gkrania-Klotsas E; Gouliouris T; Baker S; Navapurkar V
    Clin Infect Dis; 2022 Aug; 75(1):e97-e101. PubMed ID: 34718446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.
    Frank S; Capriotti J; Brown SM; Tessema B
    Ear Nose Throat J; 2020 Nov; 99(9):586-593. PubMed ID: 32520599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing povidone-iodine to reduce the risk of SARS-CoV-2 infection and transmission: a narrative review.
    Lim NA; Teng O; Ng CYH; Bao LXY; Tambyah PA; Quek AML; Seet RCS
    Ann Med; 2022 Dec; 54(1):1488-1499. PubMed ID: 35594333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 HaploGraph: visualization of SARS-CoV-2 haplotype spread in Japan.
    Nakagawa S; Katayama T; Jin L; Wu J; Kryukov K; Oyachi R; Takeuchi JS; Fujisawa T; Asano S; Komatsu M; Onami JI; Abe T; Arita M
    Genes Genet Syst; 2023 Nov; 98(5):221-237. PubMed ID: 37839865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 Antibody Response to Symptoms Indicative of COVID-19 in a Non-Infected Population in Japan: a Cross-Sectional Study.
    Tanaka S; Umezawa J; Yamaji T; Abe SK; Hamada A; Kobayashi O; Ushijima T; Inoue M
    Jpn J Infect Dis; 2023 Jan; 76(1):46-54. PubMed ID: 36184396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.